Evidence map›Paper›PMID 36982173›Full record

ArticleInternational journal of molecular sciences2023

Biological Activity of Oleanolic Acid Derivatives HIMOXOL and Br-HIMOLID in Breast Cancer Cells Is Mediated by ER and EGFR.

Natalia Lisiak, Patrycja Dzikowska, Urszula Wisniewska, Mariusz Kaczmarek, Barbara Bednarczyk-Cwynar, Lucjusz Zaprutko, Blazej Rubis

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Natalia LisiakDepartment of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Rokietnicka 3 St., 60-806 Poznan, Poland.
Patrycja DzikowskaDepartment of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Rokietnicka 3 St., 60-806 Poznan, Poland.
Urszula WisniewskaDepartment of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Rokietnicka 3 St., 60-806 Poznan, Poland.
Mariusz KaczmarekDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Garbary 15 St., 61-866 Poznan, Poland.ORCID 0000-0002-6282-3251
Barbara Bednarczyk-CwynarDepartment of Organic Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6 St., 60-780 Poznan, Poland.ORCID 0000-0003-2958-9106
Lucjusz ZaprutkoDepartment of Organic Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6 St., 60-780 Poznan, Poland.ORCID 0000-0003-1121-6272
Blazej RubisDepartment of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Rokietnicka 3 St., 60-806 Poznan, Poland.ORCID 0000-0003-1730-0176
Poznan University of Medical Sciences · PL

Funding

Poznan University of Medical Sciences Own funds of Department of Clinical Chemistry and Molecular Diagnostics
6 · The paper itself

Abstract

Breast cancer is one of the most frequently observed malignancies worldwide and represents a heterogeneous group of cancers. For this reason, it is crucial to properly diagnose every single case so a specific and efficient therapy can be adjusted. One of the most critical diagnostic parameters evaluated in cancer tissue is the status of the estrogen receptor (ER) and epidermal growth factor receptor (EGFR). Interestingly, the expression of the indicated receptors may be used in a personalized therapy approach. Importantly, the promising role of phytochemicals in the modulation of pathways controlled by ER and EGFR was also demonstrated in several types of cancer. One such biologically active compound is oleanolic acid, but due to poor water solubility and cell membrane permeability that limits its use, alternative derivative compounds were developed. These are HIMOXOL and Br-HIMOLID, which were demonstrated to be capable of inducing apoptosis and autophagy or diminishing the migratory and invasive potential of breast cancer cells in vitro. In our study, we revealed that proliferation, cell cycle, apoptosis, autophagy, and also the migratory potential of HIMOXOL and Br-HIMOLID in breast cancer cells are mediated by ER (MCF7) and EGFR (MDA-MB-231) receptors. These observations make the studied compounds interesting in the context of anticancer strategies.

Indexed as

Breast NeoplasmsOleanolic AcidApoptosisCell Line, TumorCell ProliferationErbB ReceptorsFemaleHumansReceptors, Estrogen12-bromo-3-hydroxyimonoolean-28-13-olideEGFR protein, humanErbB Receptorsmethyl 3-hydroxyimino-11-oxoolean-12-en-28-oateOleanolic AcidReceptors, Estrogenbreast cancerBr-HIMOLIDEGFRERHIMOXOLoleanolic acid

Identifiers

PMID36982173
PMCPMC10048893
OpenAlexW4323568104

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read87
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.